These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 2852446)

  • 41. Partial agonistic action of clozapine at dopamine D2 receptors in dopamine depleted animals.
    Ninan I; Kulkarni SK
    Psychopharmacology (Berl); 1998 Feb; 135(3):311-7. PubMed ID: 9498736
    [TBL] [Abstract][Full Text] [Related]  

  • 42. On the selectivity and specificity of the antagonism of apomorphine-induced suppression of exploration by sulpiride.
    Ståhle L; Ungerstedt U
    Psychopharmacology (Berl); 1989; 99(1):75-9. PubMed ID: 2528780
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Stimulation of dopamine D2 receptors induces an analgesia involving an opioidergic but non enkephalinergic link.
    Michael-Titus A; Bousselmame R; Costentin J
    Eur J Pharmacol; 1990 Oct; 187(2):201-7. PubMed ID: 2176983
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of D1 receptor mechanisms in the potentiation of motor responses to L-dopa and apomorphine by MK 801 in the reserpine-treated mouse.
    Kaur S; Starr MS; Starr BS
    J Neural Transm Park Dis Dement Sect; 1994; 8(1-2):107-16. PubMed ID: 7893372
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Motor depression: a new role for D1 receptors?
    Chandler CJ; Wohab W; Starr BS; Starr MS
    Neuroscience; 1990; 38(2):437-45. PubMed ID: 2148204
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dopamine D1 and D2 receptors mediate opposite effects of apomorphine on the body temperature of reserpinized mice.
    Costentin J; Duterte-Boucher D; Panissaud C; Michael-Titus A
    Neuropharmacology; 1990 Jan; 29(1):31-5. PubMed ID: 1968237
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chronic electroconvulsive shock alters hypothermic response of B-HT 920 and SKF 38393 in rats.
    Verma A; Kulkarni SK
    J Pharm Pharmacol; 1991 Nov; 43(11):813-4. PubMed ID: 1686915
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Potentiation of dopamine-dependent locomotion by clonidine in reserpine-treated mice is restricted to D2 agonists.
    Starr MS; Starr BS
    J Neural Transm Park Dis Dement Sect; 1994; 7(2):133-42. PubMed ID: 7710665
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Influence of SCH 23390, a DA1-receptor antagonist, on the behavioural responsiveness to small and large doses of apomorphine in rats.
    Cuomo V; Cagiano R; Colonna M; Renna G; Racagni G
    Neuropharmacology; 1986 Nov; 25(11):1297-300. PubMed ID: 2948132
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Electroconvulsive treatment attenuates behavioral response to SKF 38393 in reserpine-treated mice.
    Hao XZ; Mathé AA; Mathé JM; Svensson TH
    Psychopharmacology (Berl); 1990; 100(1):135-7. PubMed ID: 2296622
    [TBL] [Abstract][Full Text] [Related]  

  • 51. D-1 and D-2 receptor blockade have additive cataleptic effects in mice, but receptor effects may interact in opposite ways.
    Klemm WR; Block H
    Pharmacol Biochem Behav; 1988 Feb; 29(2):223-9. PubMed ID: 3283778
    [TBL] [Abstract][Full Text] [Related]  

  • 52. B-HT 958 stimulates dopamine autoreceptors but blocks noradrenaline autoreceptors in the brain.
    Grabowska-Andén M; Andén NE
    J Pharm Pharmacol; 1984 Nov; 36(11):748-52. PubMed ID: 6150978
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Locomotor effects of amantadine in the mouse are not those of a typical glutamate antagonist.
    Starr MS; Starr BS
    J Neural Transm Park Dis Dement Sect; 1995; 9(1):31-43. PubMed ID: 7605588
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of dopamine D1 and D2 receptor agonists and antagonists on seizures induced by chemoconvulsants in mice.
    Ogren SO; Pakh B
    Pharmacol Toxicol; 1993; 72(4-5):213-20. PubMed ID: 8103921
    [TBL] [Abstract][Full Text] [Related]  

  • 55. (+)-AJ 76 and (+)-UH 232: central stimulants acting as preferential dopamine autoreceptor antagonists.
    Svensson K; Johansson AM; Magnusson T; Carlsson A
    Naunyn Schmiedebergs Arch Pharmacol; 1986 Nov; 334(3):234-45. PubMed ID: 2880302
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bromocriptine induces marked locomotor stimulation in dopamine-depleted mice when D-1 dopamine receptors are stimulated with SKF38393.
    Jackson DM; Hashizume M
    Psychopharmacology (Berl); 1986; 90(1):147-9. PubMed ID: 3094056
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bromocriptine induces climbing behaviour: possible D-1 or D-2 dopamine receptor involvement.
    Zarrindast MR; Shahed-Dirin K
    Psychopharmacology (Berl); 1990; 100(2):275-80. PubMed ID: 2305016
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Postsynaptic dopamine/adenosine interaction: I. Adenosine analogues inhibit dopamine D2-mediated behaviour in short-term reserpinized mice.
    Ferré S; Herrera-Marschitz M; Grabowska-Andén M; Ungerstedt U; Casas M; Andén NE
    Eur J Pharmacol; 1991 Jan; 192(1):25-30. PubMed ID: 1828236
    [TBL] [Abstract][Full Text] [Related]  

  • 59. B-HT 958--an antagonist at alpha 2-adrenoceptors and an agonist at dopamine autoreceptors in the brain.
    Hörtnagl H; Pichler L; Holzer-Petsche U; Hornykiewicz O; Kobinger W
    Eur J Pharmacol; 1984 Nov; 106(2):335-44. PubMed ID: 6152218
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibition of K+-stimulated [3H]dopamine and [14C]acetylcholine release by the putative dopamine autoreceptor agonist, B-HT 920.
    Schmidt CJ; Lobur A; Lovenberg W
    Naunyn Schmiedebergs Arch Pharmacol; 1986 Dec; 334(4):377-82. PubMed ID: 2434870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.